Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).

James R. Berenson, Robert Vescio, Robert Dichmann et al.|Journal of Clinical Oncology|2013

Cited by 3